STOCK TITAN
  1. Home
  2. Sec-filings
  3. LLY
  4. [8-K] Eli Lilly & Co. Reports Material Event

LLY submits Form 8-K to post June-quarter results press statement

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Eli Lilly and Company filed a Form 8-K dated 7 Aug 2025 under Item 2.02 to furnish, not file, a press release (Ex. 99.1) that announces the company’s financial results for the quarter ended 30 Jun 2025. The actual earnings figures are not included in this submission; investors must review the accompanying press release for details. No other material transactions or disclosures are presented. The filing re-affirms the company’s NYSE listings for its common stock and various note issues and indicates that Lilly is not an emerging-growth company. The document is purely administrative and carries no immediate financial metrics or guidance.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Administrative 8-K furnishes Q2 2025 earnings release; no numbers provided—impact neutral.

The filing merely signals that Lilly has released its second-quarter results via a separate press release. Because the actual revenue, EPS, or guidance data are absent, investors receive no new quantitative insight from this document alone. Its purpose is compliance—ensuring Regulation FD disclosure—and it neither alters valuation nor risk profile without the accompanying exhibit. As such, I view the market impact as neutral pending review of the press release itself.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Understanding 8-K Material Events →
0000059478false00000594782025-08-072025-08-070000059478us-gaap:CommonClassAMember2025-08-072025-08-070000059478lly:A1.625NotesDueJune22026Member2025-08-072025-08-070000059478lly:A2.125NotesDueJune32030Member2025-08-072025-08-070000059478lly:A625Notesdue2031Member2025-08-072025-08-070000059478lly:A500NotesDue2033Member2025-08-072025-08-070000059478lly:A6.77NotesDueJanuary12036Member2025-08-072025-08-070000059478lly:A1625NotesDue2043Member2025-08-072025-08-070000059478lly:A1.700Notesdue2049Member2025-08-072025-08-070000059478lly:A1125NotesDue2051Member2025-08-072025-08-070000059478lly:A1375NotesDue2061Member2025-08-072025-08-07

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 7, 2025
ELI LILLY AND COMPANY
(Exact Name of Registrant as Specified in its Charter) 
Indiana 001-06351 35-0470950
(State or Other Jurisdiction
of Incorporation)		 (Commission
File Number)		 (I.R.S. Employer
Identification No.)
  


Lilly Corporate Center
Indianapolis,Indiana46285
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (317) 276-2000

Not Applicable
(Former Name or Former Address, if Changed Since Last Report.) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock (no par value)LLYNew York Stock Exchange
1.625% Notes due 2026LLY26New York Stock Exchange
2.125% Notes due 2030LLY30New York Stock Exchange
0.625% Notes due 2031LLY31New York Stock Exchange
0.500% Notes due 2033LLY33New York Stock Exchange
6.77% Notes due 2036LLY36New York Stock Exchange
1.625% Notes due 2043LLY43New York Stock Exchange
1.700% Notes due 2049LLY49ANew York Stock Exchange
1.125% Notes due 2051LLY51New York Stock Exchange
1.375% Notes due 2061LLY61New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 2.02. Results of Operations and Financial Condition.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.

Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated August 7, 2025, announcing the financial results of Eli Lilly and Company for the quarter ended June 30, 2025.





Item 9.01. Financial Statements and Exhibits.

Exhibit No.Description
99.1
Press Release of Eli Lilly and Company, dated August 7, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).













































SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELI LILLY AND COMPANY
(Registrant)
By:/s/ Donald A. Zakrowski
Name:Donald A. Zakrowski
Title:Senior Vice President, Finance, and
Chief Accounting Officer
Date: August 7, 2025

Source: View Original Filing on SEC EDGAR

FAQ

What did Eli Lilly (LLY) file on August 7 2025?

The company filed a Form 8-K to furnish its Q2 2025 earnings press release under Item 2.02.

Does the Form 8-K contain Eli Lilly's Q2 2025 financial numbers?

No. The actual financial metrics are in Exhibit 99.1, which is referenced but not reproduced in the filing text provided.

Which period’s results are covered by the press release?

The results pertain to the quarter ended June 30, 2025.

Is the press release deemed "filed" or "furnished"?

It is expressly furnished, meaning it is not subject to Section 18 liability unless incorporated elsewhere.

Did the filing disclose any other material events?

No additional material transactions, guidance updates, or leadership changes were disclosed.